Actinogen secures FDA agreement to advance Xanamem for Alzheimer’s disease

Actinogen Medical (ASX:ACW) has reached a critical regulatory milestone in its bid to bring a novel Alzheimer’s treatment to market, securing agreement with the US Food and Drug Administration (FDA) on the path forward for its lead therapy, Xanamem (emestedastat). …